11,440 results match your criteria Bone Marrow Transplantation[Journal]


Outcome of αβ T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission.

Bone Marrow Transplant 2019 Apr 15. Epub 2019 Apr 15.

Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Research Сenter of Pediatric Hematology, Oncology and Immunology, Samory Mashela street, 1, Moscow, 117997, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0531-3DOI Listing
April 2019
1 Read

Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications.

Bone Marrow Transplant 2019 Apr 15. Epub 2019 Apr 15.

Department of Pediatric Hematology and Oncology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0530-4DOI Listing

Wine, war and hematology.

Authors:
Shaun R McCann

Bone Marrow Transplant 2019 Apr 11. Epub 2019 Apr 11.

Haematology Emeritus, University of Dublin Trinity College, Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0358-3DOI Listing

Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects.

Bone Marrow Transplant 2019 Apr 10. Epub 2019 Apr 10.

Department of Hematology, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0526-0DOI Listing

Donor assessment and follow-up: not a minor issue.

Bone Marrow Transplant 2019 Apr 10. Epub 2019 Apr 10.

Division of Pediatric Hematology, Oncology and BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0529-xDOI Listing

Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors.

Bone Marrow Transplant 2019 Apr 10. Epub 2019 Apr 10.

Departments of Medicine, Psychiatry, Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA.

Understanding the potential emotional and psychological risks of pediatric sibling HSC donation is an area of research that remains in its infancy. A cross-sectional survey was distributed electronically to directors at all CIBMTR and EBMT centers to describe current transplant center practices for obtaining assent, preparation for the physical/emotional experiences of donation, and monitoring the post-donation well-being of pediatric donors (<18 years of age). Respondents were 45/91 (49%) and 66/144 (46%) of CIBMTR and EBMT centers, respectively. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0515-3
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0515-3DOI Listing
April 2019
8 Reads

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

Bone Marrow Transplant 2019 Apr 8. Epub 2019 Apr 8.

Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.

We retrospectively reviewed the impact of impaired renal function (eGFR < 45 ml/min/SA) on post-transplant outcomes in patients receiving ASCT for AL amyloidosis. Patients were grouped into two cohorts, those with normal renal function (NRF) eGFR ≥ 45 ml/min (n = 568) and those with impaired renal function (IRF) eGFR < 45 ml/min (n = 87). Patients with IRF had higher renal stage (>Stage 1: 100% IRF vs 37% NRF, p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0524-2DOI Listing

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.

Bone Marrow Transplant 2019 Apr 8. Epub 2019 Apr 8.

Department of Medical Sciences, Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.

Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic stem cell transplantation (allo-HSCT). We investigated the indications for allo-HSCT, clinical outcome, management of relapse, and post-transplant TKI treatment in a population-based setting using the Swedish CML registry. Of 118 CML patients transplanted between 2002 and 2017, 56 (47. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0513-5DOI Listing
April 2019
1 Read

Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis.

Bone Marrow Transplant 2019 Apr 8. Epub 2019 Apr 8.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF). Therefore Rux, when given prior to hematopoietic cell transplantation (HCT) in patients with MF was hypothesized to improve engraftment, decrease incidence and severity of graft-versus-host disease, and lower non-relapse mortality (NRM). We conducted a phase II prospective trial to assess the effects of pre-HCT Rux on post-HCT outcomes in patients with MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0523-3DOI Listing
April 2019
1 Read

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019.

Bone Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Hopital Saint Antoine, Sorbonne Université, Paris, France.

This is the seventh special EBMT report on the indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on transplant indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered together with the risk of the disease, the risk of the transplant procedure and the results of non-transplant strategies. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0516-2
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0516-2DOI Listing
April 2019
6 Reads

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes.

Bone Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.

Fever is a common early complication after infusion of stem cells in patients undergoing T-replete HLA haploidentical transplantation using post-transplant cyclophosphamide (PTCY). We analyzed the records of 172 haploidentical transplant patients to identify risk factors and to assess the impact of such fevers on transplant morbidity and mortality. One hundred and seventy-two patients received haploidential hematopoietic stem cell transplantation (haplo-HSCT) using PBSC (n = 103) or marrow (n = 69) grafts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0522-4DOI Listing
April 2019
1 Read

Fertility preservation from the point of view of hematopoietic cell transplant specialists-a worldwide-web-based survey analysis.

Bone Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

The Reproductive Medicine and IVF Unit, Kaplan Medical Center, Pasternak Street, 76100, Rehovot, Israel.

With the increase in cancer survival, men and women have a chance to conceive children post-recovery. This study aims to better understand hematopoietic cell transplant (HCT) specialist practices and opinions related to fertility preservation for hematological malignancy patients. Survey requests were emailed to 586 European Society for Blood and Marrow Transplantation (EBMT) members. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0519-zDOI Listing

High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.

HLA matching is a critical factor for successful allogeneic hematopoietic stem cell transplantation. For unrelated donor searches, matching is usually based on high-resolution typing at five HLA loci, looking for a 10/10 match. Some studies have proposed that further matching at the haplotype level could be beneficial for clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0520-6DOI Listing

Art, Labels and Wine: you can't judge a book by its cover.

Authors:
Shaun R McCann

Bone Marrow Transplant 2019 Apr 5. Epub 2019 Apr 5.

Haematology Emeritus, Trinity College, University of Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0517-1DOI Listing
April 2019
1 Read

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).

Bone Marrow Transplant 2019 Apr 1. Epub 2019 Apr 1.

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

The original version of this article included some minor typesetting errors in Table 1-a corrected version of which is provided in this correction article and has been corrected in the original article-and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as 'Springer Nature Limited', however, since the article is Open Access, the copyright holders should in fact be 'The Author(s)'. This has also been corrected in the original article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0507-3DOI Listing
April 2019
2 Reads

Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL.

Bone Marrow Transplant 2019 Mar 27. Epub 2019 Mar 27.

Department of Hematology, Institute of Hematology, Changhai Hospital, 200433, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0514-4DOI Listing
March 2019
1 Read

Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation.

Bone Marrow Transplant 2019 Mar 27. Epub 2019 Mar 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0518-0DOI Listing

Causal inference in randomized clinical trials.

Bone Marrow Transplant 2019 Mar 26. Epub 2019 Mar 26.

Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0424-xDOI Listing

CRISPR/Cas9-modified hematopoietic stem cells-present and future perspectives for stem cell transplantation.

Bone Marrow Transplant 2019 Mar 22. Epub 2019 Mar 22.

University Children's Hospital, Department of Pediatrics I, Hematology and Oncology, University of Tübingen, Tübingen, Germany.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a standard therapeutic intervention for hematological malignancies and several monogenic diseases. However, this approach has limitations related to lack of a suitable donor, graft-versus-host disease and infectious complications due to immune suppression. On the contrary, autologous HSCT diminishes the negative effects of allogeneic HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0510-8DOI Listing
March 2019
1 Read

Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Mar 21. Epub 2019 Mar 21.

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

The aim of this study was to evaluate the frequency of severe cardiac complications and to assess the ability of various factors to predict these complications in severe aplastic anaemia (SAA) patients after haploidentical transplantation. A retrospective study was conducted in 216 consecutive SAA patients who underwent haploidentical transplantation from 2006 to 2017. All patients received a unified regimen including busulfan, cyclophosphamide (CTX) and antithymocyte globulin at a single centre. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0509-1
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0509-1DOI Listing
March 2019
4 Reads

Early posttransplant plasma ADAMTS13 activity reduction in stem cell transplantation: a prospective study of 46 pediatric patients.

Bone Marrow Transplant 2019 Mar 19. Epub 2019 Mar 19.

Department of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Kobe, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0506-4DOI Listing

Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer.

Bone Marrow Transplant 2019 Mar 19. Epub 2019 Mar 19.

QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

The effect of anti-thymocyte globulin (ATG) on the outcome of hematopoietic stem cell transplantation (SCT) is dependent on formulation, dose and exposure. However, ATG levels are not routinely measured and therapeutic levels are not well defined. In ex vivo T cell-deplete SCT, the potential effect of residual ATG has important implications on the timing of adoptive T cell transfer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0505-5DOI Listing
March 2019
1 Read

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

Bone Marrow Transplant 2019 Mar 19. Epub 2019 Mar 19.

Hematology Department, Institut Paoli Calmettes, Marseille, France.

While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus conducted a detailed analysis evaluating the incidence, risk factors, and prevalence of GVHD after PBSC Haplo-SCT with PT-Cy. One hundred and eighty-one patients with hematological diseases were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0500-xDOI Listing
March 2019
1 Read

Donor-derived CD4/CCR7 T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide.

Bone Marrow Transplant 2019 03 19. Epub 2019 Mar 19.

LIRIC, Inserm U995, Université de Lille, 59000, Lille, France.

In previous studies, we and others observed in patients undergoing HLA-matched hematopoietic cell transplantation that high proportion of donor-derived CD4/CCR7 T cells were associated with an increased risk of acute GVHD without any interference in relapse incidence. We investigated the impact of donor-derived CD4/CCR7 T cells on patient outcome in haploidentical settings where posttransplant cyclophosphamide is used. We analyzed T-cell subsets in grafts of 29 adult patients who underwent first haploidentical transplant following reduced intensity conditioning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0511-7DOI Listing

Author Correction: Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement.

Bone Marrow Transplant 2019 Mar 19. Epub 2019 Mar 19.

Division of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany.

In the original article, the affiliations were presented incorrectly. David Petroff is in fact the only author at affiliation 2. All other authors listed as being at affiliation 2 (Tina Weiße, Sebastian Beer, Franziska Gnatzy, Joachim Mössner, Michael Tröltzsch, Johannes Wiegand and Volker Keim) are in fact just at affiliation 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0512-6DOI Listing
March 2019
1 Read

ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation.

Bone Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

The effects of ABO incompatibility on hematopoietic stem cell transplantation remain controversial. Large cohorts are required to obtain findings that allow for definite conclusions. We previously demonstrated poor overall survival and increased treatment-related mortality (TRM) in ABO-incompatible unrelated bone marrow transplantation (UR-BMT) performed during the period from 1993 to 2005. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0496-2
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0496-2DOI Listing
March 2019
4 Reads

Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation.

Bone Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

Antithymocyte globulin (ATG) is an important component of conditioning regimens to prevent graft-versus-host disease (GVHD) in unrelated hematopoietic stem cell transplantation (HSCT), but the optimal dose of ATG remains unknown. We prospectively analyzed 205 unrelated HSCTs in patients with malignant hematological disorders. HSCTs were classified as follows: HLA-matched transplant without ATG (n = 53, group A), HLA-mismatched transplant treated with 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0502-8DOI Listing
March 2019
6 Reads

Stents, Anticoagulants and Wine.

Authors:
Shaun R McCann

Bone Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Haematology Emeritus, University of Dublin Trinity College, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0503-7DOI Listing

Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host.

Bone Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Hematology Department-Hematopoietic Cell Transplantation Unit, Gene and Cell Therapy Center, "George Papanikolaou" Hospital, Thessaloniki, 57010, Greece.

Invasive aspergillosis (IA) represents a leading cause of mortality in immunocompromised patients. Although adoptive immunotherapy with Aspergillus-specific T cells (Asp-STs) represents a promising therapeutic approach against IA, the complex and costly production limits its broader application. We generated Asp-STs from a single blood draw of healthy individuals or IA patients in only 10 days, by either Aspergillus fumigatus (AF) lysate or peptide stimulation of mononuclear cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0501-9DOI Listing
March 2019
2 Reads
3.570 Impact Factor

Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.

Bone Marrow Transplant 2019 Mar 12. Epub 2019 Mar 12.

Department of Haematology, Freeman Hospital, Newcastle Upon Tyne, UK.

In the original version of this article, the mention of 'ifosfamide 1500 mg/m days 1-3' should, in fact, read 'ifosfamide 1500 mg/m bd days 1-3'. This has now been updated in the original version of the article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0504-6DOI Listing

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.

Bone Marrow Transplant 2019 Mar 4. Epub 2019 Mar 4.

Department of Hematology, Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for many malignant high-risk hematological diseases. The Graft-vs.-Tumor (GvT) effect is the major hallmark of this treatment approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0498-0DOI Listing
March 2019
2 Reads

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.

Bone Marrow Transplant 2019 Mar 4. Epub 2019 Mar 4.

Acute Leukemia Working Party of the EBMT, Hopital Saint-Antoine, Paris, France.

The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0499-zDOI Listing
March 2019
3 Reads

Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Division of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany.

Allogeneic hematopoietic stem cell transplantation is the only curative option for a variety of diseases. Despite advances, it is associated with considerable morbidity and mortality, often involving liver complications. Liver disease can be characterized using ultrasound-based liver stiffness measurement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0464-xDOI Listing
February 2019
1 Read

Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0494-4DOI Listing
February 2019
2 Reads

Patients age: so does wine.

Authors:
Shaun R McCann

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Professor Emeritus of Haematology and Academic Medicine, St James' Hospital and Trinity College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0490-8DOI Listing
February 2019
1 Read

Dr Hans August Messner 1941-2018.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Department of Hematology, Ottawa, ON, Canada.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0495-3
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0495-3DOI Listing
February 2019
5 Reads

Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Medical University Department, Clinic for Endocrinology/Metabolism/Clinical Nutrition, Kantonsspital Aarau, Aarau, Switzerland.

Survival after allogeneic stem cell transplantation (allo-HSCT) has improved, but so have long-term sequelae. We studied risk factors for fractures and impaired bone health in allo-HSCT patients in the Basel HSCT registry from 01/2003 to 12/2014 using cox proportional models adjusted for age, gender and Karnofsky Index. Our primary endpoint was the incidence of fractures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0484-6DOI Listing
February 2019
2 Reads

MBI-LCBI and CLABSI: more than scrubbing the line.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0489-1
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0489-1DOI Listing
February 2019
5 Reads

Effects of smoking on outcomes of hematopoietic cell transplantation: a systemic review and future directions.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Hematopoietic cell transplantation (HCT) survivors are at risk of increased mortality compared to the general population. Smoking by HCT survivors has been reported to impact a variety of health outcomes, resulting in an increased risk for infections, cardio-pulmonary diseases, and cancer. The purpose of our study was to conduct a systematic literature search to determine the relationship between tobacco smoking pre-HCT and post-HCT outcomes. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0485-5
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0485-5DOI Listing
February 2019
9 Reads

Early and late hematologic toxicity following CD19 CAR-T cells.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

Autologous T cells transduced with CD19-directed chimeric antigen receptors have recently been approved by several regulatory agencies for the treatment of relapsed and refractory leukemia and lymphoma, after demonstrating remarkable remission rate in advanced patients. The most common adverse events reported are cytokine-release syndrome (CRS), neurotoxicity, and hematologic toxicity. Here, we focus on early and late cytopenia occurring after CD19 CAR-T cells in 38 patients treated with CD19 CAR-T cells. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0487-3
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0487-3DOI Listing
February 2019
20 Reads

Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD).

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Traditional severity criteria of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) were determined retrospectively but found inappropriate for therapeutic decisions. Data of 203 patients with SOS/VOD were collected according to the modified Seattle diagnostic criteria and were analyzed for validation of the revised severity criteria recently proposed from European Society for Blood and Marrow Transplantation (EBMT). According to the traditional severity criteria, none of the patients were mild grade, while 63. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0492-6DOI Listing
February 2019